Coverage
Filings
| Filing | Date |
|---|---|
| Novo Nordisk, own shares (section 28) | 18 Aug 2006 |
| Novo Nordisk, insiders' tradings | 18 Aug 2006 |
| Novo Nordisk, insiders' tradings | 14 Aug 2006 |
| Novo Nordisk, insiders' tradings | 11 Aug 2006 |
| Novo Nordisk, insiders' tradings | 7 Aug 2006 |
| Novo Nordisk, interim report - six months | 2 Aug 2006 |
| Novo Nordisk, own shares (section 28) | 4 Jul 2006 |
| Novo Nordisk, articles of association as per 8 March 2006 | 27 Jun 2006 |
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| Novo Nordisk, own shares (section 28) |
| 23 Jun 2006 |
| Novo Nordisk, insiders' tradings | 15 May 2006 |
| Novo Nordisk, insiders' tradings | 10 May 2006 |
| Novo Nordisk, insiders' tradings | 8 May 2006 |